These findings mirror our preclinical data and suggest the initial clinical relevance of high FAK-YAP signaling in the RD state in NSCLC patient tumors, an area for future validation in larger clinical cohorts as they become available. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.